3 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 3 |
Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Nab paclitaxel plus gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 300 | 2021-09-01 | 2022-01-28 |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 600 | 2021-04-01 | 2021-04-08 |
| Brazilian Total Neoadjuvant Therapy Trial Folfirinox - Colorectal Neoplasms | Phase 3 | Unknown | Hospital Israelita Albert Einstein | 150 | 2020-02-20 | 2023-10-11 |
Colorectal Neoplasms (1) · Rectal Neoplasms (1)
Fudan University (2) · Hospital Israelita Albert Einstein (1)
Brazil (1) · China (1)
Diogo Gomes, MD (1) · Xian-Jun Jun, M.D., Ph.D. (1) · Xian-Jun Yu, MD, PhD (1)